First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics (Nasdaq: TRAX) announced that its executives are scheduled to participate in five investor conferences during November and December 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

First Tracks Biotherapeutics (Nasdaq: TRAX) announced that its executives are scheduled to participate in five investor conferences during November and December 2026.

Appearances include Guggenheim in Boston on November 10, Jefferies in London on November 16, UBS in London on November 17, Piper Sandler in New York on December 1, and Evercore in Miami on December 2. Live webcasts and replays lasting at least 30 days will be available through the investor website.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/03/2026 - 04:15 PM EST

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today announced that members of its executive team are scheduled to participate in multiple upcoming investor conferences:

Guggenheim 3^rd Annual Healthcare Innovation Conference, Boston

Format – Fireside chat and one-on-one investor meetings
Date and Time – Tuesday, Nov. 10, 2026 at 11:30am ET

Jefferies Global Healthcare Conference, London

Format – Presentation and one-on-one investor meetings
Date and Time – Monday, Nov. 16, 2026 at 4:30pm GMT / 11:30am ET

UBS Global Biopharma Conference 2026, London

Format – Fireside chat and one-on-one investor meetings
Date and Time – Tuesday, Nov. 17, 2026 at 11:40am GMT / 6:40am ET

Piper Sandler 38^th Annual Healthcare Conference, New York

Format – Fireside chat and one-on-one investor meetings
Date and Time – Tuesday, Dec. 1, 2026 at 1:30pm ET

9^th Annual Evercore Healthcare Conference, Miami

Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Dec. 2, 2026 at 12:30pm ET

Live webcasts of the presentation and fireside chats will be available on the investor section of the First Tracks website at https://ir.firsttracksbio.com/news-events/events. Replays of the webcasts will be available for at least 30 days following the events.

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator. To learn more, visit www.FirstTracksBio.com or follow us on LinkedIn.

Investor Contact:
Nick Montemarano
Vice President, Investor Relations
858.732.0178
investors@firsttracksbio.com